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ABSTRACT
Background: An understanding of whether homocysteine is a cause
or a marker of increased blood pressure is relevant because blood
homocysteine can be effectively lowered by safe and inexpensive
interventions (e.g., vitamin B-6, B-9, and B-12 supplementation).
Objective: The aim was to assess the causal influence of homocys-
teine on systolic and diastolic blood pressure (SBP and DBP, respec-
tively) in adults with the use of Mendelian randomization (MR).
Design: Data from the 1982 Pelotas Birth Cohort (Brazil) were used.
A total of 4297 subjects were evaluated in 2004–2005 (mean age:
22.8 y). The association of homocysteine concentration with SBP and
DBP was assessed by conventional ordinary least-squares (OLS) linear
regression and 2-stage least-squares (2SLS) regression (MR analysis).
The single nucleotide polymorphism (SNP) methylenetetrahydrofolate
reductase (MTHFR) C677T (rs1801133) was used as proxy for
homocysteine concentration. We also applied MR to data from the
International Consortium for Blood Pressure (ICBP) genomewide as-
sociation studies (.69,000 participants) using rs1801133 and addi-
tional homocysteine-associated SNPs as instruments.
Results: In OLS regression, a 1-SD unit increase in log homocys-
teine concentration was associated with an increase of 0.9 (95% CI:
0.4, 1.4) mm Hg in SBP and of 1.0 (95% CI: 0.6, 1.4) mm Hg in
DBP. In 2SLS regression, for the same increase in homocysteine,
the coefficients were21.8 mmHg for SBP (95% CI:23.9, 0.4 mmHg;
P = 0.01) and 0.1 mm Hg for DBP (95% CI: 21.5, 1.7 mm Hg;
P = 0.24). In the MR analysis of ICBP data, homocysteine concen-
tration was not associated with SBP (b = 0.6 mm Hg for each 1-SD
unit increase in log homocysteine; 95% CI: 20.8, 1.9 mm Hg) but
was positively associated with DBP (b = 1.1 mm Hg; 95% CI: 0.2,
1.9 mm Hg). The association of genetically increased homocysteine
with DBP was not consistent across different SNPs.
Conclusion: Overall, the present findings do not corroborate the
hypothesis that homocysteine has a causal role in blood pressure,
especially in SBP. Am J Clin Nutr 2016;103:39–49.
Keywords: blood pressure, cohort studies, homocysteine, Mende-
lian randomization, molecular epidemiology
INTRODUCTION
A higher risk of coronary artery disease is observed among
subjects with very high plasma homocysteine concentrations, as
in some rare genetic defects, including mutations in the gene
encoding cystathionine b-synthase (CBS).5 This finding raised
the hypothesis that homocysteine might be involved in the
etiology of cardiovascular diseases (CVDs) (1, 2).
The association between homocysteine and CVD was initially
replicated in retrospective studies, but subsequent prospective
studies yielded considerably weaker associations (3, 4), raising
the concern that the association of hyperhomocysteinemia with
CVD risk in the general population could be explained by reverse
causality or residual confounding (5). On the other hand, this
association has biological plausibility, because homocysteine has
been associated with increased blood pressure (6, 7).
The use of genetic variants as instruments to improve causal
inference in observational studies is known as Mendelian
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randomization (MR). The term comes from Mendel’s laws of
inheritance, stating that allele pairs separate to form gametes
(first law) and that alleles in different loci segregate in-
dependently from each other during gamete formation (second
law) (8). In contrast to traditional observational studies, MR is
not as susceptible to confounding, measurement error, and re-
verse causality, because genotype is defined at conception, ge-
netic variants can be precisely measured, and their distribution is
usually independent of “classical” confounders such as socio-
economic and lifestyle characteristics, provided that there is no
population stratification (9, 10).
MR has been used previously to investigate the potential causal
role of homocysteine in coronary artery disease (11) and stroke
(12) with the use of a single nucleotide polymorphism (SNP) in
the gene encoding the enzyme 5,10-methylenetetrahydrofolate
reductase (MTHFR) as an instrumental variable (IV) for circu-
lating homocysteine concentration. This SNP, known asMTHFR
C677T (rs1801133), consists of a cytosine to thymidine sub-
stitution at nucleotide 677 in MTHFR. This results in an alaline
to valine substitution at codon 222 of the enzyme, which is
detrimental for its activity and leads to an important increase in
blood homocysteine concentrations. In a previous meta-analysis,
the association between this SNP and coronary disease was
modest or negligibly different from zero (11). The association
with stroke varied according to geographical location, with null
findings in European, North American, and Australian studies
and positive findings in Asian studies. This heterogeneity might
be attributed to effect modification by folate intake or to small-
study bias (12).
An understanding of the causal role of hyperhomocysteinemia
in vascular disease and its risk factors, including blood pressure,
is relevant because homocysteine concentration can be effec-
tively lowered by simple, safe, and inexpensive interventions,
such as supplementation with folic acid, vitamin B-6, and vitamin
B-12 (13, 14). This study’s aim was to assess the causal influence
of homocysteine on blood pressure in adults with the use of the
MR approach.
METHODS
Data sources
This study included individual-level data from the 1982
Pelotas Birth Cohort and summary data from the following dif-
ferent consortia: the International Consortium for Blood Pressure
(ICBP) (15), the largest meta-analysis of genomewide association
studies (GWASs) for homocysteine concentration available (16),
the Global Lipids Genetics Consortium (GLGC) (17), the Meta-
Analyses of Glucose and Insulin-Related Traits Consortium
(MAGIC) (18, 19), and the Genetic Investigation of Anthropo-
metric Traits (GIANT) Consortium (20, 21). Details about each
data source are provided below.
1982 Pelotas Birth Cohort
Participants
Pelotas is a medium-sized city, with nearly 330,000 in-
habitants, located in the south of Brazil. In 1982, all maternity
hospitals in the city were visited daily, and 99.2% of the births
were identified. Those live-born infants whose families lived in
the urban area of the city were evaluated and their mothers
interviewed (n = 5914). These subjects have been followed up
on several occasions. Further details of the study methodology
have been described elsewhere (22, 23). In 2004–2005, 4297
members of the cohort (mean age: 22.8 y; range: 21.9–23.7 y)
were evaluated, which, when added to the 282 known to have
died, represented a follow-up rate of 77.4%. The subjects an-
swered a questionnaire and had venous blood samples collected.
Variables
Systolic and diastolic blood pressure (SBP and DBP, re-
spectively) were measured at the beginning and at the end of the
interview by using a calibrated digital wrist blood pressure
monitor (Omron HEM-629) on the left arm. Before each mea-
surement, the individual was instructed to sit and rest for at least
5 min. The mean of the 2 measurements was used. The circulating
homocysteine concentration was determined by chemiluminescence
immunoassay (24) with the use of the Immulite System (Siemens
Health Care Diagnostics).
DNA was extracted from peripheral blood leukocytes by se-
quential lysis with the use of the salting-out technique, adapted
from the protocol by Miller et al. (25). After extraction, DNAwas
frozen at 2708C. Genotyping was performed by using the
Illumina HumanOmni2.5-8v1 array (Illumina Inc.). Quality-control
exclusion criteria for SNPs consisted of a Hardy-Weinberg
equilibrium P value ,1 3 1027, being monomorphic, and
a genotyping rate ,95%. For individuals, exclusion criteria
were as follows: missing information for .3% of genotyped
SNPs and cryptic relatedness [kinship .0.1, as described else-
where (26)]. For this study, we used the SNP MTHFR C677T as
an instrument due to its well-characterized and strong associa-
tion with circulating homocysteine concentrations.
Covariates were as follows: sex (male or female), skin color
(white, black, brown, or other), years of education (0–4, 5–8, 9–
11, or $12 y), family income (quintiles of minimum wage
units), regular alcohol intake (nondrinkers, ,2 drinks/d, and
$2 drinks/d; 1 drink = 15 g alcohol), leisure-time physical ac-
tivity (,150 or $150 min/wk), current smoking (0, 1–10, 11–20,
or .20 cigarettes/d), and BMI (in kg/m2; underweight: ,18.5;
normal weight: 18.5–24.9; overweight: 25–29.9; or obese: $30).
Weight and height, used in BMI calculation, were measured by
using standard criteria (27).
Summary data
ICBP
The ICBP initiative conducted a meta-analysis of 29GWASs for
blood pressure including .69,000 individuals of European an-
cestry and 2.5 million genotyped or imputed SNPs (15). The
analyses were performed by using an additive genetic model and
were adjusted for age, age squared, BMI, antihypertensive med-
ication use, study-specific variables, and genomic control inflation
factor. We directly requested summary data on the association of
SNPs with SBP and DBP from ICBP investigators.
Meta-analysis of GWASs for homocysteine concentration
The meta-analysis included data from 10 GWASs on homo-
cysteine concentration with a total of 44,147 individuals of
European ancestry. Analyses were performed on sex-specific and
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age-adjusted SD units of natural log-transformed homocysteine
concentration and by using an additive genetic model. Genomic
control was used in each cohort before the meta-analysis. We
extracted data on the association of SNPs with homocysteine
concentration directly from van Meurs et al. (16).
GLGC
The GLGC included 60 cohort and case-control studies with
GWAS or Metabochip data and HDL-cholesterol, LDL-choles-
terol, and triacylglycerol data for 188,577 individuals of Euro-
pean ancestry (17). Analyses were performed by using an
additive genetic model and were adjusted for age, sex, study-
specific variables, and genomic control inflation factor. In-
dividuals taking lipid-lowering medications were excluded. Data
on the association of SNPs with HDL cholesterol, LDL cho-
lesterol, and triacylglycerol were downloaded from http://csg.
sph.umich.edu/abecasis/public/lipids2013/.
MAGIC
MAGIC included 23 cohort studies with GWAS and glycated
hemoglobin (HbA1c) data on 38,238 individuals of European
ancestry (18) and 20 cohort studies with GWAS and fasting
insulin data on 35,920 individuals of European ancestry (19).
Analyses were performed by using an additive genetic model and
were adjusted for age, sex, cohort-specific variables, and genomic
control inflation factor (l). Data on the association of SNPs with
HbA1c and fasting insulin were downloaded from http://www.
magicinvestigators.org/downloads/.
GIANT
GIANT included 114 studies of multiple designs with GWAS
or Metabochip and BMI data on 38,238 individuals of European
ancestry (20) and 101 studies of multiple designs with GWAS or
Metabochip and waist circumference (WC) data on 210,088
individuals of European ancestry (21). BMI analyses were per-
formed by using an additive genetic model and were adjusted for
age, age squared, study-specific variables, and genomic control
inflation factor (l). WC analyses were adjusted for sex, BMI,
study-specific variables, and genomic control inflation factor
(l). Data on the association of SNPs with BMI and WC were
downloaded from http://www.broadinstitute.org/collaboration/
giant/index.php/GIANT_consortium_data_files.
Data analysis
1982 Pelotas Birth Cohort
Multinomial regression models were used to verify ifMTHFR
C677T genotype distribution was associated with the covariates
(sex, skin color, years of education, family income, regular al-
cohol consumption, leisure-time physical activity, smoking, and
BMI). Homocysteine was log transformed, due to its positively
skewed distribution, and standardized (SD units). Crude and
adjusted (for sociodemographic and lifestyle variables) associ-
ations of standardized log homocysteine concentration with SBP
and DBP were evaluated by using conventional ordinary least-
squares (OLS) linear regression (Figure 1).
MR analysis of the association of standardized log homo-
cysteine concentration with SBP and DBP was performed by using
2-stage least-squares (2SLS) regression, which is an IVestimation
technique (28). In the first stage, homocysteine concentration is
regressed against the IV. The second stage consists of regressing
the values of SBP and DBP against the predicted values of the first
model. The MTHFR C677T variant was coded in the additive
genetic model according to the number of copies of the T allele.
FIGURE 1 Analysis plan. Individual data from the 1982 Pelotas Birth Cohort were used to estimate the association of homocysteine concentration with
SBP and DBP [unadjusted “crude” model and adjusted for potential confounders (“adjusted*” model)] and to investigate the association of genetically
increased homocysteine concentration with SBP and DBP [MR analysis; unadjusted “crude” model and adjusted for genomic ancestry (“adjusted**” model)].
Summary data from the ICBP and homocysteine GWASs were combined to further investigate the association of genetically increased homocysteine
concentration with SBP and DBP (MR analysis) by using as an IV the SNP MTHFR C677T (single SNP approach) or 18 SNPs associated with homocysteine
concentration (multiple SNP approach). DBP, diastolic blood pressure; GWAS, genomewide association study; Hcy, homocysteine; ICBP, International
Consortium for Blood Pressure; IV, instrumental variable; IVW, inverse variance weighted; MR, Mendelian randomization; MTHFR, methylenetetrahydro-
folate reductase; OLS, ordinary least-squares linear regression; SBP, systolic blood pressure; SNP, single nucleotide polymorphism; 2SLS, 2-stage least-
squares regression.
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Results from OLS and 2SLS regression were compared by using
the Durbin-Wu-Hausman (DWH) test (28–31) (Figure 1).
To control for population stratification, analyses were adjusted
for the top 10 ancestry-informative principal components (cal-
culated by using a linkage disequilibrium–pruned subset of
655,046 autosomal SNPs) (32).
Summary data
To further explore the potential causal effect of homocysteine
concentration on SBP and DBP, we also analyzed summary data
from the ICBP. All SNP effect alleles were harmonized to reflect
homocysteine-increasing alleles.
Two approaches were applied to the ICBP data, here referred to
as “single SNP” and “multiple SNP” approaches (Figure 1). In the
single SNP approach, only the SNP MTHFR C677T (rs1801133)
was used as an IV, which has a well-established functional role in
homocysteine concentration. The IV b-coefficients and SEs were
calculated by using the inverse variance weighted (IVW) method
[described by Burgess et al. (33)], as follows:
bIVW ¼
X Y r2 2y
X2 r2 2y
SEbIVW ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
X2 r2 2y
s
ð1Þ
where X is the mean change in standardized log homocysteine
concentration per additional effect allele of MTHFR C677T and
Y is the mean change in SBP or DBP (mm Hg) per additional
effect allele of MTHFR C677T with SE sy.
In the multiple SNP approach, all SNPs associated with
homocysteine concentration in the largest GWAS available (16)
were used, regardless of evidence of a functional impact of the
SNP on homocysteine concentration (n = 18 SNPs). Charac-
teristics of these SNPs and their association with the studied
phenotypes are summarized in Supplemental Table 1. Data
from the 18 SNPs were used 1) to estimate the average effect of
the SNPs on homocysteine concentration, SBP, and DBP by
using a fixed-effects meta-analysis model with inverse variance
weights and the heterogeneity of the association across SNPs,
measured by I2, and 2) to investigate the effect of genetically
increased homocysteine concentration on SBP and DBP (IV
estimation).
The IVestimation for the multiple SNP approach was based on
2 methods. The first was the IVW method, in which IVestimates
for each SNP (indexed by k) were combined in a fixed-effects
meta-analysis model (33), as follows:
bIVW ¼
P
k XkYkr
2 2
ykP
k X
2
kr
2 2
yk
SEbIVW ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1P
k X
2
kr
2 2
yk
s
ð2Þ
In case $1 SNPs influence SBP or DBP independently of
homocysteine concentration (horizontal pleiotropy) and such
direct effects do not cancel out, MR assumptions are violated
and IV estimates from the IVW method will be biased. To ac-
count for horizontal pleiotropy, a second IV estimation method
was used in the multiple SNP approach, the MR-Egger re-
gression method, recently proposed by Bowden et al. (34).
The MR-Egger regression is an adaptation of the Egger re-
gression, in which a regression model is fitted by using regression
coefficients for SNP-outcome (SBP or DBP) associations as the
dependent variable and regression coefficients for SNP-exposure
(homocysteine) as the independent variable, weighting by the
inverse variance of SNP-outcome associations. In this method,
the intercept will reflect the average horizontal pleiotropic effect
across genetic variants and the slope will be a valid causal effect
estimate provided that the InSIDE (Instrument Strength In-
dependent of Direct Effect) assumption holds, which requires that
there is no correlation between SNP-exposure associations and
direct effects of SNPs on the outcome. Bootstrapping (10,000
iterations) was used to derive corrected 95% CIs for MR-Egger
intercept and slope by using the percentile method (34).
As a sensitivity analysis, to further explore the issue of hor-
izontal pleiotropy, the same IVs (both single SNP and the
multiple SNP approaches with the IVW method) were used to
investigate the association of genetically increased homocysteine
concentration with the following phenotypes: HDL cholesterol,
LDL cholesterol, triacylglycerol, fasting insulin, HbA1c, BMI,
and WC.
All analyses were performed with Stata 12.1 software (Stata-
Corp). Stata ivregress command was used for 2SLS regression
models (35).
Ethical issues
All phases of the 1982 Pelotas Birth Cohort Study were ap-
proved by the Research Ethics Committee of the Federal Uni-
versity of Pelotas, which is affiliated with the Brazilian Federal
Medical Council. Written informed consent was obtained from
participating subjects in the 2004–2005 visit.
RESULTS
1982 Pelotas Birth Cohort
A total of 3701 individuals had complete genotyping, blood
pressure, and biochemical data. Most individuals self-reported as
white, had completed 9–11 y of formal education, drank up to
2 drinks of alcohol/d, were inactive during leisure time, were
nonsmokers, or had a normal BMI (Table 1).
The MTHFR C677T SNP was in Hardy-Weinberg equilib-
rium (P = 0.49) and was associated with skin color (P , 0.001),
but this association disappeared after adjustment for the top
10 ancestry-informative principal components (P = 0.91). None
of the covariates tested were associated with the MTHFR C677T
variant after this adjustment (Table 2).
Men had higher concentrations of homocysteine (9.0 mmol/L;
95% CI: 8.9, 9.2 mmol/L) and higher SBP (123.4 mm Hg; 95%
CI: 122.8, 124.1 mm Hg) and DBP (75.6 mm Hg; 95% CI: 75.0,
76.1 mm Hg) than did women (homocysteine: 7.1 mmol/L; 95%
CI: 7.0, 7.2 mmol/L; SBP: 111.2 mm Hg; 95% CI: 110.6,
111.8 mm Hg; and DBP: 71.2 mm Hg; 95% CI: 70.7, 71.7 mm Hg).
The following characteristics were also positively associated
with homocysteine concentration and SBP and/or DBP: low
educational level, high alcohol intake, and being physically
active. Smoking was positively associated with homocysteine
concentration and negatively with DBP. Family income, skin
color, and BMI were associated with SBP and DBP but not
with homocysteine concentration (Table 3).
The MTHFR C677T SNP explained 5.3% of the variance in
homocysteine concentration (F statistic = 208, P = 6 3 10246).
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The T allele was associated with higher homocysteine concentra-
tions in both sexes. Men with TT and CT genotypes had, on av-
erage, a 1.3- and a 0.2-SD higher log homocysteine concentration,
respectively, compared with men with the CC genotype. In women,
this difference wasw 0.7 and 0.2 SDs. There was no clear evidence
of an association of MTHFR C677T with SBP or DBP (Figure 2).
In unadjusted OLS regression, a 1-SD unit increase in log
homocysteine concentration was associated with mean increases
of 0.9 mm Hg (95% CI: 0.4, 1.4 mm Hg) in SBP and of 1.0 mm
Hg (95%CI: 0.6, 1.4 mmHg) in DBP. In the sex-specific analysis,
the coefficients were 0.7 mm Hg (95% CI: 0.0, 1.4 mm Hg) for
SBP and 0.9 mm Hg (95% CI: 0.3, 1.4 mm Hg) for DBP among
men and 1.2 mm Hg (95% CI: 0.6, 1.8 mm Hg) for SBP and
1.2 mm Hg (95% CI: 0.7, 1.7 mm Hg) for DBP among women.
Adjustment for socioeconomic and lifestyle variables did not
substantially change these estimates (Figure 3).
According to the IV analysis of individual-level data (2SLS
regression), the coefficients for a 1-SD increase in log homo-
cysteine concentration were 21.8 mm Hg (95% CI: 23.9,
0.4 mm Hg) for SBP and 0.1 mm Hg (95% CI:21.5, 1.7 mm Hg)
for DBP. In the sex-specific analysis, the coefficients were20.2 mm
Hg (95% CI:22.5, 2.1 mm Hg) in men and22.3 mm Hg (95% CI:
25.9, 1.3 mm Hg) in women for SBP and 0.7 mm Hg (95% CI:
21.1, 2.5 mm Hg) in men and 20.2 mm Hg (95% CI: 23.1,
2.8 mmHg) in women for DBP. Adjustment for ancestry-informative
principal components slightly changed these estimates (Figure 3).
None of the results from MR analysis of the Pelotas data were sig-
nificantly different from zero. With regard to the comparison between
regression coefficients from OLS and 2SLS, there was some evidence
that the coefficients differed for SBP when considering the whole
sample (P = 0.01, DWH test) but not for DBP (P = 0.24, DWH test).
Summary data
The analysis of ICBP data indicated that the SNPs rs154657
and rs234709 were negatively associated with SBP and/or DBP.
TABLE 1
Sociodemographic and lifestyle characteristics of participants from the
1982 Pelotas Birth Cohort, 2004–2005
n (%)
Sex
Male 1860 (50.3)
Female 1841 (49.7)
Skin color
White 2768 (74.8)
Black 597 (16.1)
Brown 196 (5.3)
Other 140 (3.8)
Years of education
0–4 302 (8.2)
5–8 1042 (28.2)
9–11 1817 (49.1)
$12 540 (14.6)
Family income, quintile
1 (poorest) 774 (20.9)
2 754 (20.4)
3 723 (19.5)
4 712 (19.2)
5 (wealthiest) 738 (19.9)
Alcohol consumption
Nondrinkers 1203 (32.5)
,2 drinks/d 1864 (50.4)
$2 drinks/d 634 (17.1)
Leisure-time physical activity
Inactive (,150 min/wk) 2595 (70.1)
Active ($150 min/wk) 1106 (29.9)
Smoking
Nonsmokers 2745 (74.2)
1–10 cigarettes/d 513 (13.9)
11–20 cigarettes/d 375 (10.1)
.20 cigarettes/d 68 (1.8)
BMI
Underweight 216 (5.8)
Normal weight 2407 (65.1)
Overweight 770 (20.8)
Obese 305 (8.3)
Total 3701 (100.0)
TABLE 2
Genotype distribution according to covariates in the 1982 Pelotas Birth
Cohort, 2004–2005
rs1801133, %
n CC CT TT P1 P2
Sex 0.13 0.09
Male 1860 49.6 41.6 8.8
Female 1841 46.3 44.3 9.4
Skin color ,0.001 0.91
White 2768 44.8 45.3 9.8
Black 597 60.8 33.2 6.0
Brown 196 54.1 38.8 7.1
Other 140 45.7 43.6 10.7
Years of education 0.24 0.85
0–4 302 48.3 41.7 9.9
5–8 1042 49.5 41.6 8.9
9–11 1817 48.5 42.5 8.9
$12 540 42.6 47.8 9.6
Family income, quintile 0.23 0.57
1 (poorest) 774 47.7 42.6 9.7
2 754 52.5 39.9 7.6
3 723 47.4 43.7 8.9
4 712 46.8 43.4 9.8
5 (wealthiest) 738 45.1 45.3 9.6
Alcohol consumption 0.70 0.81
Nondrinkers 1203 49.3 41.3 9.4
,2 drinks/d 1864 47.1 43.9 9.1
$2 drinks/d 634 48.0 43.4 8.7
Leisure-time physical activity 0.20 0.45
Inactive (,150 min/wk) 2595 44.0 44.8 11.2
Active ($150 min/wk) 1106 48.3 42.8 8.9
Smoking 0.27 0.59
Nonsmokers 2745 47.3 43.7 9.0
1–10 cigarettes/d 513 52.5 37.6 9.9
11–20 cigarettes/d 375 45.9 44.8 9.3
.20 cigarettes/d 68 47.0 45.6 7.4
BMI 0.73 0.76
Underweight 216 48.6 42.6 8.8
Normal weight 2407 47.5 43.6 8.9
Overweight 770 49.2 40.5 10.3
Obese 305 47.9 44.3 7.9
Total 3701 47.9 43.0 9.1
1P values for heterogeneity (multinomial logistic regression).
2P values adjusted for the top 10 ancestry-informative principal com-
ponents (multinomial logistic regression).
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The SNP rs1801133 (MTHFR C677T) was the only SNP that
was positively associated with DBP. Heterogeneity across SNPs
was high for the association with homocysteine concentration
(I2 = 94%, P , 0.001) and moderate for the association with
SBP (I2 = 40%, P-heterogeneity = 0.04) and DBP (I2 = 41%,
P = 0.04) (Figure 4).
FIGURE 2 Standardized mean (95% CI) values for log homocysteine, SBP, and DBP according to genotypes of MTHFR C677T (rs1801133) in men and
women combined (A), men (B), and women (C): 1982 Pelotas Birth Cohort, 2004–2005. Values were adjusted for the top 10 ancestry-informative principal
components. A total of 1774 individuals had the CC genotype (922 men and 852 women), 1590 had the CT genotype (774 men and 816 women), and 337 had
the TT genotype (164 men and 173 women). DBP, diastolic blood pressure; HCY, homocysteine; SBP, systolic blood pressure.
TABLE 3
Homocysteine, SBP, and DBP according to covariables in the 1982 Pelotas Birth Cohort, 2004–20051
n
Homocysteine,2
mmol/L SBP, mm Hg DBP, mm Hg
Sex
Male 1860 9.0 (8.9, 9.2) 123.4 (122.8, 124.1) 75.6 (75.0, 76.1)
Female 1841 7.1 (7.0, 7.2) 111.2 (110.6, 111.8) 71.2 (70.7, 71.7)
Skin color
White 2768 8.0 (7.9, 8.1) 116.9 (116.4, 117.5) 73.3 (72.9, 73.7)
Black 597 8.0 (7.8, 8.2) 119.0 (117.7, 120.2) 74.1 (73.1, 75.1)
Brown 196 8.0 (7.6, 8.4) 118.5 (116.4, 120.6) 73.4 (71.6, 75.2)
Other 140 8.1 (7.7, 8.6) 117.9 (115.3, 120.4) 72.7 (70.8, 74.6)
Years of education
0–4 302 8.6 (8.3, 9.0) 117.5 (115.8, 119.2) 72.9 (71.6, 74.3)
5–8 1042 8.2 (8.0, 8.4) 118.0 (117.0, 118.9) 72.9 (72.2, 73.7)
9–11 1817 7.8 (7.7, 7.9) 117.6 (116.9, 118.3) 73.9 (73.3, 74.4)
$12 540 8.0 (7.8, 8.2) 115.4 (114.2, 116.5) 73.0 (72.2, 73.8)
Family income, quintile
1 (poorest) 774 8.1 (7.9, 8.3) 116.2 (115.1, 117.2) 72.7 (71.9, 73.6)
2 754 8.0 (7.8, 8.2) 117.6 (116.5, 118.7) 73.5 (72.6, 74.3)
3 723 7.9 (7.7, 8.1) 117.4 (116.3, 118.6) 73.3 (72.5, 74.1)
4 712 8.0 (7.8, 8.1) 118.1 (117.0, 119.1) 73.7 (72.9, 74.5)
5 (wealthiest) 738 8.1 (7.9, 8.3) 117.7 (116.6, 118.7) 73.8 (73.0, 74.6)
Alcohol consumption
Nondrinkers 1203 7.7 (7.6, 7.9) 115.7 (114.9, 116.5) 73.2 (72.6, 73.9)
,2 drinks/d 1864 8.0 (7.9, 8.1) 117.1 (116.5, 117.8) 73.3 (72.9, 73.8)
$2 drinks/d 634 8.7 (8.4, 8.9) 121.9 (120.8, 123.0) 74.8 (73.9, 75.6)
Leisure-time physical activity
Inactive (,150 min/wk) 2595 7.8 (7.7, 7.9) 116.1 (115.6, 116.6) 73.8 (72.8, 74.9)
Active ($150 min/wk) 1106 8.5 (8.3, 8.6) 120.7 (119.9, 121.6) 73.5 (73.2, 73.9)
Smoking
Nonsmokers 2745 7.9 (7.8, 8.0) 117.5 (116.9, 118.0) 73.9 (73.4, 74.3)
1–10 cigarettes/d 513 8.2 (7.9, 8.4) 116.9 (115.7, 118.2) 72.5 (71.5, 73.5)
11–20 cigarettes/d 375 8.8 (8.5, 9.1) 116.9 (115.4, 118.5) 71.3 (70.1, 72.4)
.20 cigarettes/d 68 8.5 (7.7, 9.3) 119.8 (115.7, 123.8) 73.4 (70.4, 76.3)
BMI
Underweight 216 8.2 (7.9, 8.6) 110.1 (108.2, 111.8) 69.5 (68.1, 70.9)
Normal weight 2407 8.0 (7.9, 8.1) 115.6 (115.1, 116.2) 72.1 (71.7, 72.5)
Overweight 770 8.1 (7.9, 8.3) 121.4 (120.3, 122.5) 75.8 (75.0, 76.7)
Obese 305 8.0 (7.7, 8.3) 126.1 (124.2, 128.0) 80.1 (78.6, 81.5)
Total 3701 8.0 (7.9, 8.1) 117.4 (116.9, 117.8) 73.4 (73.0, 73.8)
1Values are means with 95% CIs in parentheses unless otherwise indicated. DBP, diastolic blood pressure; SBP,
systolic blood pressure.
2Values are geometric means of log homocysteine concentration.
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In the MR analysis using theMTHFR C677T variant as the IV
(single SNP approach), homocysteine was not associated with
SBP (b = 0.6 mm Hg/SD log homocysteine; 95% CI: 20.8,
1.9 mm Hg/SD log homocysteine) but was positively associated
with DBP (b = 1.1 mm Hg/SD log homocysteine; 95% CI: 0.2,
1.9 mm Hg/SD log homocysteine). When the 18 SNPs were
combined in the multiple SNP approach, genetically increased
homocysteine concentration was not associated with SBP or
DBP in either the IVW (SBP: b = 20.6 mm Hg; 95% CI: 21.3,
0.1 mm Hg; DBP: b =20.3 mm Hg; 95% CI:20.8, 0.1 mm Hg)
or in the MR-Egger regression method (SBP: b = 20.2 mm Hg;
95% CI:21.9, 1.5 mm Hg; DBP: b = 0.7 mm Hg; 95% CI:20.4,
1.7 mm Hg) (Figure 3).
Figure 5 shows that there was no dose-response relation
between the effect of the SNPs on the outcomes (SBP or DBP)
or on homocysteine concentration. In addition, the intercepts
from the MR-Egger regression method provided no clear evi-
dence of an effect of the SNPs on SBP or DBP independently of
homocysteine concentration [intercept: 20.03 (95% CI: 20.15,
0.09) mm Hg for SBP and20.08 (95% CI:20.16, 0.00) mm Hg
for DBP], indicating that it is unlikely that findings from the
multiple SNP approach (especially for SBP) could be explained
by horizontal pleiotropy (Figures 3 and 5).
In the MR analysis of other traits (blood lipids and glycemic
and anthropometric traits), no association was observed when the
SNP MTHFR C677T was used as the IV; however, when the
multiple SNP approach was considered, there was a positive
association with LDL cholesterol (Supplemental Figure 1).
DISCUSSION
Overall, our findings supported a positive association between
homocysteine concentration and blood pressure in young adults
in the conventional observational analysis. However, in the MR
analysis, there was no compelling evidence that genetically in-
creased homocysteine concentration was associated with blood
pressure, especially for SBP.
Similar to previous studies (7, 36), our findings from con-
ventional regression analysis support that homocysteine con-
centration is positively associated with SBP and DBP among
young adults. This association is biologically plausible. Some of
the mechanisms by which homocysteine could influence blood
pressure include oxidative stress, inflammation, and inhibition of
nitric oxide synthesis (37–39), which might result in arterial
stiffening and impaired endothelium-dependent vasodilation
(40–42). However, because homocysteine concentration is as-
sociated with sociodemographic, lifestyle, and metabolic char-
acteristics, it is difficult to conclude from conventional observational
analyses whether homocysteine is a cause or just a marker of risk
of CVDs.
Early randomized controlled trials showed that homocysteine-
lowering interventions could improve blood pressure (40, 43, 44).
FIGURE 3 Mean difference in SBP and DBP per standardized unit of log homocysteine. Observational results were estimated by using (ordinary least-
squares) linear regression (n = 3701 individuals from the Pelotas Birth Cohort) [crude model, adjusted for sociodemographic variables (adjusted model 1), and
adjusted for sociodemographic and lifestyle variables (adjusted model 2)]. MR results were estimated for individual data from the 1982 Pelotas Birth Cohort
(n = 3701 young adults) by using 2-stage least-squares regression [crude and adjusted for principal components of genomic ancestry (PCA-adjusted)] and for
summary data from the ICBP (n .69,000 adults) by using the IVW method for both the single SNP and the multiple SNP approaches and the MR-Egger
regression method for the multiple SNP approach only. DBP, diastolic blood pressure; ICBP, International Consortium for Blood Pressure; IVW, inverse
variance weighted; MR, Mendelian randomization; PCA, principal components analysis; SBP, systolic blood pressure; SNP, single nucleotide polymorphism.
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However, findings from larger trials did not provide evidence of
any improvement in SBP and DBP after folic acid supplemen-
tation, even though homocysteine concentration was substantially
decreased (45–47).
To improve causal inference in the homocysteine–blood
pressure association, we used MR to evaluate whether a genetic
variant that is functionally associated with higher concentrations
of homocysteine is also associated with blood pressure. MR
studies explore the fact that the segregation of alleles during
meiosis is analogous to the randomization process in random-
ized controlled trials, with the advantage that the “randomiza-
tion of alleles” occurs at conception and thus reflects life-long
FIGURE 4 Forest plot of the mean difference in homocysteine concentration, SBP, and DBP per effect allele of 18 SNPs. The effect from all SNPs was
combined into an overall effect by using fixed-effects meta-analysis (with inverse variance weights). Summary data were extracted from the largest
homocysteine genomewide association study available (16) and from the International Consortium for Blood Pressure (15). CBS, cystathionine beta-
synthase; CPS1, carbamoyl-phosphate synthase 1; CUBN, cubilin; DBP, diastolic blood pressure; DPEP1, dipeptidase 1; FANCA, Fanconi anemia
complementation group A; FUT2, fucosyltransferase 2; GTPBP10, GTP-binding protein 10; Hcy, homocysteine; HNF1A, HNF1 homeobox A; MMACHC,
methylmalonic aciduria cblC type; MTHFR, methylenetetrahydrofolate reductase; MTR, 5-methyltetrahydrofolate-homocysteine methyltransferase; MUT,
methylmalonyl-CoA mutase; NOX4, NADPH oxidase 4; SBP, systolic blood pressure; SLC17A3, solute carrier family 17 member 3; SNP, single
nucleotide polymorphism.
FIGURE 5 Scatter plot of the difference in SBP and DBP according to homocysteine concentration (n = 18 SNPs) estimated by using data from the
International Consortium for Blood Pressure. Each data point represents bs for SNP–blood pressure (y axis) and SNP-homocysteine (x axis) associations. The
fitted lines were derived from the IVW method (dashed line) and from the MR-Egger regression method (solid line). DBP, diastolic blood pressure; Hcy,
homocysteine; IVW, inverse variance weighted; MR, Mendelian randomization; SBP, systolic blood pressure; SNP, single nucleotide polymorphism.
46 BORGES ET AL.
 by guest on Septem
ber 8, 2016
ajcn.nutrition.org
D
ow
nloaded from
 
exposure to a risk factor (e.g., increased homocysteine concen-
trations).
The MR analysis of individual-level data from 3701 Brazilian
young adults did not provide clear evidence of a causal role of
homocysteine concentration in SBP and DBP. Moreover, the
DWH test provided evidence for a difference between the OLS
and 2SLS estimates for SBP, suggesting that the OLS estimate
was an overestimate of the causal effect (possibly due to residual
confounding). However, because of large CIs resulting from the
uncertainty inherent to IV analysis and our sample size, these
results were not conclusive.
MR analysis of ICBP data, including .69,000 older adults,
indicated no clear evidence of an association of homocysteine
with SBP but a possible positive effect of homocysteine con-
centration on DBP. However, it is important to emphasize that
this finding was largely influenced by the MTHFR C677T SNP
and was not consistent across the other homocysteine-associated
SNPs.
MR is a powerful tool for causal inference provided that the
following assumptions are met: 1) the genetic variant should be
associated with the exposure of interest, 2) it should be in-
dependent of exposure-outcome confounders, and 3) it should
affect the outcome only through the exposure (48). With regard
to the first assumption, a strong IV is essential to reduce im-
precision and, especially, to avoid weak instrument bias in MR
analysis (49–51). In a one-sample MR setting, in which all in-
formation about the exposure and the outcome comes from the
same sample (as in the analysis with data from the Pelotas co-
hort), weak instruments tend to bias the estimates toward the
observational estimate (OLS). In our 2-sample MR setting (first
sample: homocysteine GWASs; second sample: ICBP), in the
presence of weak instrument bias the MR estimates would likely
to be biased toward the null, because the 2 samples only par-
tially overlapped (,22% of the ICBP participants were part of
homocysteine GWASs) (52). In the one-sample MR, our IV
(MTHFR C677T) was associated with homocysteine concen-
tration, with R2 = 5.3% and an F statistic = 208 (P = 6 3 10246;
crude model), indicating that weak instrument bias is unlikely to
be substantially influencing our analyses by using data from
Pelotas cohort. In the 2-sample MR, only SNPs associated with
homocysteine concentration at genomewide significance levels
(P , 5 3 1028) were included in the analyses (16).
Because the Pelotas sample is multiethnic and highly admixed,
there could be confounding due to population stratification. From
all covariates considered, only skin color was associated with the
SNP, and this association was completely attenuated after ad-
justment for ancestry-informative principal components. This
adjustment is known to be an efficient strategy to control for
population stratification bias (32). Notably, this adjustment did
not substantially change the strength of the associations. Both
ICBP and homocysteine GWASs were restricted to individuals of
European ancestry and used procedures to control for population
structure (15, 16).
MR assumptions could also be violated in the case of hori-
zontal pleiotropy (i.e., the genetic variant affects the outcome
through pathways not mediated by the exposure or the genetic
variant is in linkage disequilibrium with another variant that itself
has pleotropic effects on the outcome). Although the presence of
pleiotropy cannot be entirely ruled out, we addressed that using 2
main approaches: 1) we restricted our analyses to one SNP
(rs1801133) with well-described functional roles in homo-
cysteine metabolism but known to influence other phenotypes,
such as folate, that might influence the outcomes independently
(53) and 2) we broadened our analysis to all SNPs associated
with homocysteine concentration in the largest GWASs avail-
able, regardless of knowledge about their functional impact,
which allowed us to investigate if the potential influence of
homocysteine on the outcomes was consistent across different
SNPs. For the second approach, we used a recently developed
method, the MR-Egger regression (34), which can assess and
account for (at the cost of reducing statistical power) horizon-
tal pleiotropic effects of genetic variants under the InSIDE
assumption.
One further issue that should be considered is that, for sum-
mary data analysis only, information for SNP-homocysteine and
SNP–blood pressure came from different sources. This ap-
proach, known as 2-sample MR, assumes that the 2 samples
came from comparable populations (54). The samples from both
the homocysteine GWAS consortium (16) and the ICBP (15)
partially overlapped and were comparable in terms of genomic
ancestry (all European-ancestry individuals from the United
States and Europe). The proportion of women was higher in the
homocysteine GWASs (82%) compared with ICBP data (most
studies had 50–60% women). In both consortia, the majority of
countries had not implemented folic acid fortification policies by
the time of data collection (55).
As mentioned before, it is impossible to empirically com-
pletely rule out that MR results are not being driven by violations
of IV assumptions. In this regard, it has been proposed that null
findings from MR may be more reliable than non-null findings
based on the logic that it is less likely that IV violations would
perfectly balance each other out, because there is only one null
value whereas there are infinite non-null possibilities (56). Al-
though DBP results were inconclusive, findings for SBP con-
sistently suggested the absence of a (strong) causal effect across
the different approaches, including evidence for a difference
between OLS and 2SLS in a 1-sample setting (in which weak
instrument bias tends to approximate these estimates) (52).
In conclusion, homocysteine concentration is associated with
SBP and DBP in both men and women in conventional regression
analysis. MR analyses do not support a causal role of homo-
cysteine in SBP in young southern Brazil adults, but results for
DBP were less conclusive. Findings from older adults (ICBP
data) corroborated the results for SBP, but it was not possible to
rule out a causal, positive effect of genetically instrumented
homocysteine on DBP; however, this association was largely
driven by a single SNP and was not consistent across other SNPs
associated with homocysteine. Overall, our findings indicate that
homocysteine is more likely a marker than a cause of increased
blood pressure, especially for SBP.
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